Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?

Overview

Journal J Oncol Pract

Specialty Oncology

Date 2016 Jun 9

PMID 27271507

Citations 5

Authors

Diana Tisnado

Jennifer Malin

Katherine Kahn

Mary Beth Landrum

Robert Fletcher

Carrie Klabunde

Steven Clauser

Selwyn O Rogers Jr

Nancy L Keating

Affiliations

Soon will be listed here.

Abstract

Purpose: Chemotherapy prolongs survival in patients with advanced non-small-cell lung cancer. However, few studies have included patients with poor performance status. This study examined rates of oncologists' recommendations for chemotherapy by patient performance status and symptoms and how physician characteristics influence chemotherapy recommendations.

Methods: We surveyed medical oncologists involved in the care of a population-based cohort of patients with lung cancer from the CanCORS (Cancer Care Outcomes Research and Surveillance) study. Physicians were queried about their likelihood to recommend chemotherapy to patients with stage IV lung cancer with varying performance status (Eastern Cooperative Oncology Group performance status 0 [good] v 3 [poor]) and presence or absence of tumor-related pain. Repeated measures logistic regression was used to estimate the independent associations of patients' performance status and symptoms and physicians' demographic and practice characteristics with chemotherapy recommendations.

Results: Nearly all physicians (adjusted rate, 97% to 99%) recommended chemotherapy for patients with good performance status, and approximately half (adjusted rate, 38% to 53%) recommended chemotherapy for patients with poor performance status (P < .001). Compared with patient factors, physician and practice characteristics were less strongly associated with chemotherapy recommendations in adjusted analyses.

Conclusion: Strong consensus among oncologists exists for chemotherapy in patients with advanced non-small-cell lung cancer and good performance status. However, the relatively high rate of chemotherapy recommendations for patients with poor performance status despite the unfavorable risk-benefit profile highlights the need for ongoing work to define high-value care in oncology and to implement and evaluate strategies to align incentives for such care.

Citing Articles

The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma.

Esmail A, Badheeb M, Alnahar B, Almiqlash B, Sakr Y, Al-Najjar E Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065760 PMC: 11279608. DOI: 10.3390/ph17070910.

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer-a study in AIO oncologists.

Buttelmann M, Hofheinz R, Krocher A, Ubbelohde U, Stintzing S, Reinacher-Schick A ESMO Open. 2023; 8(1):100761.

PMID: 36638708 PMC: 10024156. DOI: 10.1016/j.esmoop.2022.100761.

Chemotherapy Toxicity in Older Adults Optimized by Geriatric Assessment and Intervention: A Non-Comparative Analysis.

Hamid M, Hannan M, Myo Oo N, Lynch P, Walsh D, Matthews T Curr Oncol. 2022; 29(9):6167-6176.

PMID: 36135053 PMC: 9498117. DOI: 10.3390/curroncol29090484.

Beyond Performance Status.

Simcock R, Wright J Clin Oncol (R Coll Radiol). 2020; 32(9):553-561.

PMID: 32684503 PMC: 7365102. DOI: 10.1016/j.clon.2020.06.016.

Association between physician medical school ranking and patient outcomes and costs of care: observational study.

Tsugawa Y, Blumenthal D, Jha A, Orav E, Jena A BMJ. 2018; 362:k3640.

PMID: 30257919 PMC: 6156557. DOI: 10.1136/bmj.k3640.

References

Zeger S, Liang K . Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-30. View

Christmas T, Findlay M . Lung cancer treatment in New Zealand: physician's attitudes. N Z Med J. 2004; 117(1196):U931. View

Socinski M, Morris D, Masters G, Lilenbaum R . Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003; 123(1 Suppl):226S-243S. DOI: 10.1378/chest.123.1_suppl.226s. View

Weeks J, Catalano P, Cronin A, Finkelman M, Mack J, Keating N . Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367(17):1616-25. PMC: 3613151. DOI: 10.1056/NEJMoa1204410. View

Pfister D, Johnson D, Azzoli C, Sause W, Smith T, Baker Jr S . American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2003; 22(2):330-53. DOI: 10.1200/JCO.2004.09.053. View

Zafar S, Abernethy A . Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park). 2013; 27(2):80-1, 149. PMC: 4523887. View

Ramsey S, Bansal A, Fedorenko C, Blough D, Overstreet K, Shankaran V . Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. J Clin Oncol. 2016; 34(9):980-6. PMC: 4933128. DOI: 10.1200/JCO.2015.64.6620. View

Perez E . Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest. 1998; 114(2):593-604. DOI: 10.1378/chest.114.2.593. View

Grilli R, Oxman A, Julian J . Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol. 1993; 11(10):1866-72. DOI: 10.1200/JCO.1993.11.10.1866. View

10.

Delbaldo C, Michiels S, Rolland E, Syz N, Soria J, Le Chevalier T . Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev. 2007; (4):CD004569. DOI: 10.1002/14651858.CD004569.pub2. View

11.

Socinski M, Crowell R, Hensing T, Langer C, Lilenbaum R, Sandler A . Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):277S-289S. DOI: 10.1378/chest.07-1381. View

12.

Walling A, Tisnado D, Asch S, Malin J, Pantoja P, Dy S . The quality of supportive cancer care in the veterans affairs health system and targets for improvement. JAMA Intern Med. 2013; 173(22):2071-9. DOI: 10.1001/jamainternmed.2013.10797. View

13.

Schroen A, Detterbeck F, Crawford R, Rivera M, Socinski M . Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest. 2000; 118(1):129-37. DOI: 10.1378/chest.118.1.129. View

14.

Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N . Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol. 2004; 15(3):419-26. DOI: 10.1093/annonc/mdh087. View

15.

He Y, Zaslavsky A, Landrum M, Harrington D, Catalano P . Multiple imputation in a large-scale complex survey: a practical guide. Stat Methods Med Res. 2009; 19(6):653-70. PMC: 2891890. DOI: 10.1177/0962280208101273. View

16.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

17.

Prigerson H, Bao Y, Shah M, Paulk M, LeBlanc T, Schneider B . Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015; 1(6):778-84. PMC: 4828728. DOI: 10.1001/jamaoncol.2015.2378. View

18.

Keating N, Landrum M, Klabunde C, Fletcher R, Rogers S, Doucette W . Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?. J Clin Oncol. 2008; 26(15):2532-7. DOI: 10.1200/JCO.2007.15.9434. View

19.

Temel J, Greer J, Muzikansky A, Gallagher E, Admane S, Jackson V . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8):733-42. DOI: 10.1056/NEJMoa1000678. View

20.

Stinchcombe T, Detterbeck F, Lin L, Rivera M, Socinski M . Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. J Thorac Oncol. 2007; 2(9):819-26. DOI: 10.1097/JTO.0b013e31811f478a. View